Download Files:
BRD0209
SKU
HY-117822-10 mg
Category Reference compound
Tags GSK-3, Neurological Disease, PI3K/Akt/mTOR;Stem Cell/Wnt
$300 – $1,800
Products Details
Product Description
– BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC50 = 19 nM; GSK3β IC50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics (Ki = 4.2 nM, respectively). BRD0209 is a tricyclic pyrazolotetrahydroquinolinone compound. BRD0209 has the potential for the research of mood disorder diseases[1].
Web ID
– HY-117822
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C22H25N3O
References
– [1]Wagner FF, et al. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chem Biol. 2016;11(7):1952-1963.
CAS Number
– 1597439-87-6
Molecular Weight
– 347.45
Compound Purity
– 99.56
SMILES
– O=C1C2=C(N=C3C([C@]2(C)C4=CC=CC=C4)=C(C5CC5)NN3)CC(C)(C)C1
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 62.5 mg/mL (ultrasonic)
Target
– GSK-3
Pathway
– PI3K/Akt/mTOR;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.